Silence Therapeutics plc (OTCMKTS:SLNCF) Short Interest Update

Silence Therapeutics plc (OTCMKTS:SLNCF) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 600 shares, a decline of 64.7% from the July 15th total of 1,700 shares. Based on an average daily volume of 3,200 shares, the days-to-cover ratio is presently 0.2 days.

Silence Therapeutics Price Performance

OTCMKTS SLNCF traded up $0.80 during mid-day trading on Monday, reaching $6.30. The stock had a trading volume of 2,600 shares, compared to its average volume of 1,485. The company has a fifty day moving average price of $7.18 and a 200 day moving average price of $6.57. Silence Therapeutics has a 1 year low of $0.60 and a 1 year high of $14.75.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.